Join the VISIONaerieS™

Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care.

We are a publicly traded (NASDAQ: AERI), ophthalmic pharmaceutical company focused on the discovery, development and commercialisation of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye.

Glaucoma is one of the largest segments in the global ophthalmic market, exceeding $5b in 2016 in the United States, Europe and Japan. Glaucoma is a progressive disease in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, resulting in irreversible vision loss and potentially blindness. Additionally, glaucoma is a highly individualised disease and there is no direct correlation of the level of IOP at diagnosis with damage to the optic nerve.

Our first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, was approved by the United States Food & Drug Administration (FDA) in December 2017 for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Our second product, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, is a fixed dose combination of Rhopressa® and latanoprost, a widely prescribed prostaglandin analogue (PGA). We expect to file our NDA for Roclatan™ in the second quarter of 2018.

If approved, we believe Roclatan™ has the potential to be the most efficacious therapy for lowering of elevated IOP in the marketplace.

Work at Aerie in 2018

We are seeking experienced and enthusiastic self-starters for exciting opportunities in the areas of Manufacturing Operations, Quality, Engineering, Facilities and Supply Chain to meet hiring dates of early 2018. To learn more about what we do, please review the information and apply via the job listings below.

Aerie Pharmaceuticals Jobs: 1

Date Job Title Location Salary  
14/09/2018 Facilities Technician Westmeath Negotiable More Details

Our Strategy:

  • The first new chemical entity in a generation to treat patients with glaucoma
  • Designed to reduce elevated intraocular pressure (IOP), the cause of vision loss in open-angle glaucoma
  • One approved product – Rhopressa® (netarsudil ophthalmic solution) 0.02% and one late development-stage product – Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
  • Both product candidates are eye drops taken once a day in the evening
  • Each product candidate has potential multiple mechanisms of action, including the novel targeting of the diseased tissue, or main drain in the eye – the source of elevated IOP; potential for disease modification
  • Significant potential in an approximately $5 billion market in the U.S., Europe and Japan, which is expected to grow to more than $8 billion by 2023All product candidates fully owned by Aerie with patents through to at least 2030
More on Aerie's Strategy and Products 

Aerie Athlone:


Aerie currently employs 300+ located in the US and EU with plans to grow to 370 by end of 2018 and beyond in 2019. Headquartered Raleigh/Durham - NC we are also located in Irvine – CA,  Bedminster - NJ, Dublin & Malta. We are building our broader organisation in readiness for the commercialisation of our products, and the supply of same via our first manufacturing facility located in Athlone, Ireland.

Aerie have acquired the 2,650m2 IDA Advanced Technology Building in Athlone and will embark on an initial investment of $60m. A fast track start-up, our new sterile filling plant will be designed, constructed and validated for the global supply of our ophthalmic products with a target first regulatory approval & commercialization in early 2020. The plant will include end to end operations – compounding, sterile filling, and packaging with all support capabilities (QC labs, warehousing, etc.).

Our Core Values:


Back to Top